Navigation Links
Small study shows association between medication and reduction in brain amyloid levels related to AD
Date:10/10/2011

CHICAGO -- Although it is a small study and more clinical trials are needed, treatment with the medication gantenerumab appeared to result in a reduction in brain amyloid levels in patients with Alzheimer disease, according to a report published Online First by Archives of Neurology, one of the JAMA/Archives journals.

"Genetic and neuropathological evidence suggests that the accumulation of amyloid-β (Aβ) peptides in the brain is a key event in the pathophysiology of Alzheimer disease (AD)," the authors provide as background information. They note that there are several therapeutic approaches currently being investigated to lower the levels of Aβ amyloid in the brain. "We previously reported the development of gantenerumab, a potent and fully human anti-Aβ antibody that binds specifically to Aβ plaques."

Susanne Ostrowitzki, M.D., from F. Hoffmann-La Roche Ltd., Neuroscience, Basel, Switzerland, and colleagues investigated whether treatment with gantenerumab leads to a measureable reduction in the level of Aβ amyloid in the brain and to try to figure out the mechanism of amyloid reduction. The study included patients with mild-to-moderate AD and was conducted at three university medical centers. Two consecutive groups of patients were randomized to receive two to seven infusions of intravenous gantenerumab (60 or 200 mg) or placebo every four weeks. Additionally, brain tissue from two patients who had AD (tissue obtained during tumor surgery) was coincubated with gantenerumab as an ex vivo study.

"Sixteen patients with end-of-treatment positron emission tomographic scans were included in the analysis," the authors report. "The mean [average] percent change from baseline difference relative to placebo (n = 4) in cortical brain amyloid level was -15.6 percent for the 60-mg group (n = 6) and -35.7 percent for the 200-mg group (n = 6)." The authors note that "Gantenerumab induced phagocytosis [a
'/>"/>

Contact: Luca Santarelli, M.D.
luca.santarelli@roche.com
JAMA and Archives Journals
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Genes Play Role in Prognosis With Non-Small Cell Lung Cancers
2. Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer
3. Small Increase in Diabetes Risk Noted in Statin Patients
4. Small to Mid-Sized Hospitals Turn to Orion Health to Implement Health IT Solutions for Improved Patient Care and Outcomes
5. Media, small businesses invited to ACS Webinar on ways to take advantage of Chinas dynamic growth
6. Small Time Company Rolls into the Big League: Trigger Point Performance Therapy Selected to Attend Athletes' Performance NFL Combine Preparation Program
7. Visual Cues that Improve Walking for People with Movement Disorders - Study Shows Small Change in Arrangement Can Make a Big Difference in Improvement Gained
8. Small Dogs Traced Back to Middle Eastern Wolf
9. Landrieu Comments on Presidents Small Business Health Care Report
10. Small molecule with high impact
11. A Small Grass-roots Non-profit, Announces That They Haven't Gone Away and are Still Alive with Helping the Disadvantaged Children in Ukraine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 21, 2013 Artisan Business Group ... Summit: Dealmakers Conference in Long Beach, California on ... on exploring alternative finance through EB-5 immigrant investors ... legal and economic information, and updates to project ... within the EB-5 industry. , "Our goal ...
(Date:5/21/2013)... 2013 According to a May 13, 2013 ... of Botox,” Botox injections have become the most ... 2002 (Go to goo.gl/8iYbD). Although it is mostly associated with ... The injection makes facial wrinkles less visible by paralyzing facial ... about three months. This means that people who are conscious ...
(Date:5/21/2013)... Diversity Focus, a non-profit organization striving to improve the ... Creative Corridor region, is releasing results for its 2013 ... Thursday, May 23rd at 10:30 a.m. The survey ... , The survey is a critical component to the ... nurture and retain people of diverse backgrounds, cultures and ...
(Date:5/21/2013)... paper recently published in the New England Journal ... at the University of Colorado School of Medicine finds ... can be used to identify individuals at risk for ... fairly common variant of the gene for mucin-5B, a ... by the bronchial tubes. While this variant of the ...
(Date:5/21/2013)... scientific and technological research So Paulo Research Foundation, FAPESP, ... investment estimated in US$ 680 million to support 17 ... of up to eleven years, subject to continuation reviews ... for the 17 RIDCs will come from FAPESP and ... and infrastructure). Host institutions will participate in a portion ...
Breaking Medicine News(10 mins):Health News:Artisan Business Group to Host EB-5 Investment Conference in Long Beach, California 2Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2Health News:Research at the cutting edge of knowledge 2
... more likely to binge drink during pregnancy, researchers find , ... likely to drink alcohol or binge drink than other adults, ... from 2004 to 2008 found that 44.3 percent of blacks ... average of 55.2 percent. The rate of binge drinking among ...
... ... The Alliance for Climate Protection to form a global campaign representing millions of people to ... ... opportunity before us to transition to a clean energy economy and heal the planet, the ...
... , ... ... ... , ...
... had successful periodontal treatment gave birth early, study finds ... sign of a link between gum disease and premature ... periodontal disease who undergo successful treatment are less likely ... University of Pennsylvania in Philadelphia and Washington University in ...
... ... ... ... ...
... 2000, the foundation has awarded over 175 million dollars ... at Karolinska Institutet. Michael J. Fox is to receive ... and Dean Clara H. Gumpert representing the Board of ... The ceremony will take place at the private residence ...
Cached Medicine News:Health News:Blacks Less Likely to Abuse Alcohol 2Health News:National Climate Organizations Join Forces In Historic Push For Climate and Clean Energy Solutions 2Health News:National Climate Organizations Join Forces In Historic Push For Climate and Clean Energy Solutions 3Health News:Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium 2Health News:Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium 3Health News:Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium 4Health News:Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium 5Health News:Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium 6Health News:Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium 7Health News:Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium 8Health News:COPPERTONE(R) Solar Research Center Unveils Studies on Efficacy of Topical Antioxidants in Sunscreens at 2010 Annual Meeting of The American Academy of Dermatology 2Health News:COPPERTONE(R) Solar Research Center Unveils Studies on Efficacy of Topical Antioxidants in Sunscreens at 2010 Annual Meeting of The American Academy of Dermatology 3Health News:COPPERTONE(R) Solar Research Center Unveils Studies on Efficacy of Topical Antioxidants in Sunscreens at 2010 Annual Meeting of The American Academy of Dermatology 4Health News:COPPERTONE(R) Solar Research Center Unveils Studies on Efficacy of Topical Antioxidants in Sunscreens at 2010 Annual Meeting of The American Academy of Dermatology 5Health News:COPPERTONE(R) Solar Research Center Unveils Studies on Efficacy of Topical Antioxidants in Sunscreens at 2010 Annual Meeting of The American Academy of Dermatology 6Health News:Michael J. Fox to be made honorary doctor at Karolinska Institutet 2
(Date:5/21/2013)... -- Tom Daulton, CEO of Mammotome, a division of Devicor Medical ... Cincinnati chapter of the Association for ... top executive who is also a breast cancer survivor, led ... March of 2010. Daulton will be presented with the award ... Bank, on May 22. The ACG Deal Maker ...
(Date:5/21/2013)... May 21, 2013 Kepner-Tregoe (KT), the ... that 13-year veteran Chris Geraghty ... experience includes more than 20 years serving the ... manufacturing organizations. He succeeds Ray Baxter ... Kepner-Tregoe,s Chairman of the Board and CEO. ...
(Date:5/21/2013)... 2013  Armada Health Care (Armada) is pleased ... corporate website ( www.armadahealthcare.com ).  This new website ... first-to-market services and its position as the leading ... pharmacy industry. The updated website visibly ... model in delivering an extensive portfolio of services ...
Breaking Medicine Technology:Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year 2Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year 3Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 2Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 3Armada Announces New Corporate Website to Showcase Expanded Services to Specialty Pharmacy Marketplace 2
... Toll-Like Receptor 3 (TLR3) Agonist, SAN DIEGO, ... announced that the company has developed a,proprietary vaccine ... for use in both therapeutic and prophylactic vaccines., ... a Toll-like Receptor 3 (TLR3) agonist that when ...
... N.C., June 18 Pilot Therapeutics,Holdings, Inc. ... as Gene,Smart(TM) Health., (Logo: http://www.newscom.com/cgi-bin/prnh/20080618/CLW006LOGO ... gene-based nutrition, Gene Smart(TM) Health uniquely,combines breakthrough ... health, food, nutrition, and wellness markets to ...
Cached Medicine Technology:Nventa Develops Proprietary Vaccine Adjuvant 2Nventa Develops Proprietary Vaccine Adjuvant 3Nventa Develops Proprietary Vaccine Adjuvant 4Pilot Therapeutics Announces Relaunch as Gene Smart(TM) Health 2
...
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 35G x 5/8in (.50 x 16mm)...
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 25G x 5/8in (.50 x 16mm)...
... Unique product designed for LASIK surgery ... Designed to irrigate the corneal interface ... easy insertion under the flap and ... ports provide multi-directional irrigation.27G x 7/8in ...
Medicine Products: